|
|
Vaccine Detail
|
PSA:154-163 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: PSA:154-163 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007155
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MUC1
gene engineering:
- Description: This is for Prostate Cancer (NCT00004156). A synthetic peptide based on sequence corresponding to positions 154-163 of the amino acids of prostate-specific antigen (PSA), VISNDVCAQV. Upon administration, PSA:154-163 peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA (Kouiavskaia et al., 2009; NCIT_C2798).
|
| Host Response |
|
|
| References |
Gathuru et al., 2005: Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, Livingston PO. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity. Vaccine. 2005; 23(39); 4727-4733. [PubMed: 15978705].
Kouiavskaia et al., 2009: Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, Alexander RB. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(6); 655-666. [PubMed: 19483644].
NCIT_C2798: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2798]
NCT00004156: [https://clinicaltrials.gov/ct2/show/NCT00004156?term=MUC1-KLH+Vaccine%2FQS21&rank=1]
|
|
